Vijaya Diagnostic Centre Ltd Q1 FY27 Earnings Call: EBITDA Margin Expands to 42.7%, Guides High Double-Digit Growth

Vijaya Diagnostic Centre Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Operating Momentum

• Consolidated revenue of Rs.1,131 crore in Q1 FY 2026-2027, up 22.8% YoY, supported by 16.5% test volume growth and 18% patient volume growth.
• EBITDA of Rs.98 crore in Q1 FY 2026-2027 (34% YoY), with margin expanding 360 bps YoY to 42.7%.
• PAT of Rs.53 crore in Q1 FY 2026-2027 (margin 23%), up 37.6% YoY; cash PAT generation remains consistent at 26-27%.
• B2C revenue share held at 92% in Q1 FY 2026-2027, with radiology contributing 37% of revenue.
• Surplus cash of ~Rs.330 crore on the balance sheet as of Q1 FY 2026-2027, with no debt.
• Pune geography contributed ~6% of revenue (flat since acquisition 2.5 years ago) but grew 18% YoY to Rs.12.8 crore in Q1 FY 2026-2027.

Hub-and-Spoke Rollout Accelerates Across Geographies

• Total centre count reached 166 as of Q1 FY 2026-2027: 51 hubs and 115 spokes, with 26 processing units integrated within hubs.
• Added 1 hub (Gachibowli, Hyderabad) and 4 spokes in Q1 FY 2026-2027; 2 additional spokes commissioned in July 2026. The Gachibowli hub features a 160-slice cardiac CT.
• Flagship Bangalore hub at JP Nagar commissioned in July 2026 with a Rs.30 crore investment — includes digital PET-CT, 3T Omega MR with 75cm wide bore, and a central automated lab.
• FY 2026-2027 expansion target: 9 hub centers and 10-12 spoke centers; 2 hubs and 6 spokes completed as of July 2026.
• Capital expenditure guided at Rs.190-195 crore for FY 2026-2027, including land acquisition in an Andhra Pradesh medical hub (estimated Rs.8-10 crore) and a reference lab at Punjagutta.
• 9 hubs added in FY 2025-2026 across Pune, Bangalore, and Kolkata; majority of the 10 hubs have reached break-even, with absolute EBITDA loss from new centres under Rs.1 crore (~0.5% of revenue) in Q1 FY 2026-2027.

B2C Focus, Tier-2/3 Cities, and Structural Share Gains

• Mature Hyderabad cluster (~67% of revenue) grew 17% YoY in Q1 FY 2026-2027 without adding new hubs, demonstrating organic depth.
• New tier-2 hubs (Rajahmundry, Tirupati, Khammam, Krishnanagar) achieved break-even in just 2 quarters — well ahead of the typical 3-4 month extra timeline. Rajahmundry now attracts wellness customers from 150-200 km radius.
• Industry growth runs at ~13-14% (period unspecified); management noted the company historically outperforms by 4-5%, driven by the B2C model, high-end imaging, and quality reporting.
• Existing spokes (>5 years vintage) in Hyderabad grew at higher double-digit rates, indicating a gradual shift from unorganized to organized diagnostics.
• Wellness share held at 14.8% of revenue in Q1 FY 2026-2027 (vs. ~8% pre-COVID, 14.8% in FY 2025-2026), driven by tier-2 geographies without upselling. Average wellness package priced between Rs.8,000-Rs.10,000 with ~20% max discount off MRP.
• Top organized competitors are deploying capital outside Hyderabad as Vijaya holds a greater market share in the city, limiting competitive intensity from network expansion there.

Smart Reports, Radiology AI, and Age-Specific Wellness

• AI-driven "smart reports" for lifestyle wellness packages customized to patient age, history, and details, launched in Q1 FY 2026-2027.
• AI deployed in radiology for organ-based cases (KUB, chest, breast) after validation and certification by Vijaya's team of 400+ radiologists; integrated into PACS systems for unified reporting.
• Age-specific screening packages advanced: MRI brain for dementia (age 60-70), advanced cardiac imaging with cardiac angio (age 40-55), and liver elastography for liver patients.
• Differentiated wellness approach (premium packaging, multi-organ screening) being rolled out to Bengaluru, Pune, and other new geographies.
• Data monetization acknowledged as a "gold mine" but management stated data is not shared due to a strict privacy policy; monetization requires compliance clarity (period unspecified).

Cost Structure Advantages and Structural Above-40% Margins

• 60-70% of costs at existing hubs are fixed; blended cost of material consumption is ~11%, yielding an ~89% contribution margin.
• EBITDA margin of 42.7% in Q1 FY 2026-2027 (up 360 bps YoY) supported by operating leverage from mature clusters, partially offset by a ~0.5% drag from 10 hubs added in FY 2025-2026.
• 3.7 tests per patient (vs. 2.5-3 for peers) and a higher realization of Rs.1,860 per patient (vs. Rs.900-Rs.950) — driven by comprehensive test menu and B2C focus (vs. 25-30% B2B for peers).
• Management expressed confidence in sustaining EBITDA margins above 40% for FY 2026-2027, guided for a potential 1-1.5% drag from the current year's expansion while leveraging higher scale from mature clusters.
• Last price hike taken in June 2025 (Q1 FY 2025-2026), restricted to Hyderabad across select tests; no price hikes since. Management will reassess pricing strategy post Q2/Q3 FY 2026-2027.

Guidance, Growth Corridors, and Long-Horizon Targets

• High double-digit growth expected for FY 2026-2027 — management expressed confidence after reporting 23% revenue growth in Q1 FY 2026-2027.
• 3-5 year sustainable growth rate of 15% cited as "easily achievable" by management for the mid-to-long term.
• 6 additional hubs planned in the next 12 months (FY 2026-2027), building on the 9 hubs added in FY 2025-2026.
• East India and Karnataka identified as "primary growth corridors" for the next 7-8 years, expected to deliver scale similar to current Hyderabad operations — management stated, "East India and Karnataka are identified as the primary growth corridors for the next 7-8 year plan".
• 10-year vision to replicate the dense cluster hub-and-spoke model across eastern India and Karnataka, increase home collection and wellness penetration, and maintain leadership in imaging and pathology — management cited a "future vision (over the next 10 years)" to execute this strategy.
• FY 2026-2027 capex includes a one-off land purchase in Andhra Pradesh, deviating from the leasing strategy after a 6-7 year search for a suitable site in a medical hub.